Jump to: Page Content, Section Navigation, Site Navigation, Site Search, Account Information, or Site Tools.
|
|
Sci. Signal., 11 December 2012 LETTERSComment on "Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling"Barbara Burtness1,2, Shanthi Marur3, Julie E. Bauman4, Erica A. Golemis2*, Ranee Mehra1,2, and Steven J. Cohen1,2
1 Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Abstract: Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) play important roles in tumor growth, which has stimulated efforts toward the design of targeted cancer therapeutics that inhibit their function. A growing body of literature indicates that EGFR and mTOR are also essential to support a functional innate immune response. Hence, although combination therapies that block both EGFR and mTOR may have improved activity against tumors, they may also place patients at risk of fulminant infections. We discuss data supporting this hypothesis. * Corresponding author. E-mail: erica.golemis{at}fccc.edu
Citation: B. Burtness, S. Marur, J. E. Bauman, E. A. Golemis, R. Mehra, S. J. Cohen, Comment on "Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling". Sci. Signal. 5, lc5 (2012). The editors suggest the following Related Resources on Science sites:In Science Signaling
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
|
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882